A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs IPI 549 (Primary) ; Nivolumab
  • Indications Breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 12 Oct 2017 According to an Infinity Pharmaceuticals media release, updated data from this trial will be presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
    • 25 Sep 2017 According to an Infinity Pharmaceuticals media release, The combination expansion component will now also add a cohort of patients with triple negative breast cancer (TNBC) who have not been previously exposed to immune checkpoint blockade therapy.
    • 03 Aug 2017 According to an Infinity Pharmaceuticals media release, dose escalation evaluating IPI-549 in combination with Opdivo is ongoing, and the company expects to initiate the combination expansion component of the study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top